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Abstract 
Background: Pleiotropic effects on cardiovascular protection have been suggested in several oral antidiabetic drugs 
(OAD). The impacts of OADs on aortic aneurysm (AA) growth have been found in animal studies, but the evidence of 
their beneficial effects for AA protection in human are lacking. We investigated the relationship between OAD therapy 
and the risk of developing AA.
Methods: We conducted a nested case–control analysis using the database extracted from Taiwan’s National Health 
Insurance Research Database. The database consists of 1.2 million diabetic patients representing the majority of 
the type 2 diabetes population in Taiwan from 2000 to 2013. Cases were identified as those with either inpatient or 
outpatient diagnosis code of AA. One control was selected for each case matching on duration of follow‑up, age, 
sex, urbanization, monthly income, severity of diabetes, and risk factor for AA. We identified variable classes of OADs, 
including metformin, sulfonylureas, thiazolidinedione (TZD), alpha‑glucosidase inhibitors, meglitinide, dipeptidyl 
peptidase‑4 (DPP‑4) inhibitors prior to the development of AA.
Results: A total of 4468 cases diagnosed with AA and 4468 matched controls were identified. Metformin use, sulfo‑
nylurea use, and TZD were associated with lower risk of developing AA, odds ratio [OR] 0.72 (95 % confidence interval 
[CI] 0.64–0.80), 0.82 (95 % CI 0.74–0.92), and 0.82 (95 % CI 0.69–0.98), respectively. The effects of metformin and 
sulfonylurea on AA were dose responsive. Neither alpha‑glucosidase inhibitors (OR 0.95; 95 % CI 0.81–1.11) nor DPP‑4 
inhibitors (OR 0.85; 95 % CI 0.68–1.07) was significantly associated with AA events.
Conclusions: Metformin, sulfonylurea, and TZD treated patients were associated with lower risks of AA development, 
but not DPP‑4 inhibitors or alpha‑glucosidase inhibitor. The protective effects of hypoglycemic agents are further 
confirmed by the dose responsive relations in metformin and sulfonylurea groups.
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Background
Aortic aneurysm (AA) is a potentially life-threatening 
disease while progressing to aneurysm rupture. There are 
several well-established risk factors for AA development, 
including older age, male gender, hypertension, Cauca-
sian race, genetic factors, waist circumference, and other 
atherosclerotic diseases [1–4]. The hallmark of AA devel-
opment is aortic vessel wall protein destruction, and sub-
sequent transmural wall expansion. The process results 
from inflammation, oxidative stress, apoptosis, and pro-
teolysis within extracellular matrix [5, 6]. A recent pro-
spective study reported higher levels of coronary vascular 
disease biomarkers, including high-sensitivity C-reactive 
protein and heart-type fatty acid-binding protein, was 
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found in patients with small or medium size AAs [7]. 
Based on these results, the authors suggested that AAs 
might be regarded as subclinical atherosclerosis.
Pleiotropic effects on cardiovascular protection have 
been suggested in several oral antidiabetic drugs (OAD). 
Metformin, one of the oldest drugs for diabetes treat-
ment, was shown to inhibit aortic smooth muscle cell 
proliferation, and matrix metalloprotein (MMP)-2 
expression in experimental studies [8]. The thiazoli-
dinediones (TZD) modulate peroxisome proliferator-
activated receptor-γ, a nuclear hormone receptor family 
transcription factor, which affects MMP-9 activity, and 
release of cytokines [9]. Another class of OAD, dipeptidyl 
peptidase-4 (DPP-4) inhibitors, also decreases produc-
tion of reactive oxygen species (ROS) in cardiac mito-
chondria [10]. Whether the OAD-associated decrease 
in inflammation, MMP activities, and ROS produc-
tion protects aortic vessel from aneurysm formation 
remains uncertain. Previous animal studies have tested 
this hypothesis by treating apolipoprotein-E (ApoE) 
deficient mice with metformin [11], pioglitazone [12], 
rosiglitazone [9], and DPP-4 inhibitors alogliptin [13] 
and sitagliptin [14]. Development and enlargement of 
AA decreased in the OAD-treated mice. The results were 
compatible with the hypothesis.
AA is a disease of relative low incidence rate in general 
population. Therefore, it is difficult to conduct a rand-
omize control study with sufficient power to investigate 
the correlations between OAD use and development of 
AA. Thus, we designed a nested-case control analysis in 




The Taiwan National Health Insurance (NHI) program is 
a social insurance program organized by the government. 
The program was launched in 1995, providing compre-
hensive medical care, including outpatient care, emer-
gency department care, hospital care, dental services, 
medical examinations, laboratory tests, medication pre-
scriptions, and interventional procedures. It is compul-
sory for all citizens from birth, and therefore covers nearly 
all (98.4 %) of Taiwan’s population. Except for healthcare 
services, the NHI Administration was also in charge of 
the collected database of all available records from indi-
viduals involved in the insurance, composing the National 
Health Insurance Research Database (NHIRD) [15]. This 
database was released for research purposes after encryp-
tion and deidentification with removing patient’s personal 
information to protect individual privacy. Numerous high 
quality scientific research papers have been published 
using data from NHIRD [16, 17].
For this study, we used the Longitudinal Cohort of 
Diabetes Patients data set. It is validated by the Taiwan 
National Health Research Institutes for research pur-
poses [18]. This database represents most of the popula-
tion of diabetic mellitus patients in Taiwan, with a sample 
of total 1,200,000 patients diagnosed with diabetes since 
1999 [19]. It consists of deidentified secondary data for 
patient’s privacy protection. This study was approved 
by the institutional review board of Taipei City Hospital 
(TCHIRB-10404107-W), and written informed consent 
of patients was waived. The diseases were defined by the 
International Classification of Disease, Ninth Revision, 
Clinical Modification (ICD-9-CM) diagnosis codes, 2001 
edition.
Participants and control
In the nested case–control analysis, we aimed to identify 
the association between OAD use and developing of AA. 
We extracted all diabetes patients with age  ≥20  years 
between January 2000 and December 2013. Cases were 
identified as those with either inpatient or outpatient 
diagnosis code of AA (441.1, 441.2, 441.3, 441.4, 441.5, 
441.6, 441.7, and 441.9). The date when the coding of AA 
first appeared was defined as the index date. Those with 
previous aortic dissection (441.0, 441.00, 441.01, 441.02, 
and 441.03) were excluded. The accuracy of coded AA 
diagnoses in the NHIRD has been validated [20]. For 
each case, a pool of eligible controls with diagnosis of 
type 2 diabetes mellitus (DM) but without AA was cre-
ated. The index data was the date of AA for the corre-
sponding case. The same exclusion criteria were applied. 
From these eligible controls, one subject was selected 
randomly to match a case of AA according to duration 
of follow-up (cohort entry to index date), age (±5 years), 
sex, socioeconomic status, Charlson comorbidity index 
score (±3 score), adapted diabetes complications sever-
ity index score (±1 score), duration of diabetes mellitus 
(±3  months), and risk factor for AA including hyper-
tension, myocardial infarction, cerebrovascular disease, 
chronic kidney disease, and peripheral artery disease.
Exposure assessment
For the exposure of OADs, we identified variable classes 
of OADs, including metformin, sulfonylureas, TZD, 
alpha-glucosidase inhibitors, meglitinide, DPP-4 inhibi-
tors (approved in Taiwan in 2009) at any time prior to the 
index date. We collected the following information for 
each OAD prescription, including dispensing date, drug 
type, quantity, and duration of drug supply. Besides, we 
also identified the concomitant drugs which potentially 
influence the risk of AA including alpha-blocker, angi-
otensin-converting-enzyme (ACE) inhibitor or angio-
tensin II receptor blockers (ARB), beta blocker, calcium 
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channel blocker, diuretics, antiplatelet agent, warfa-
rin, statin, steroid, antidepressants, nonsteroidal anti-
inflammatory drugs (NSAID), and insulin. Moreover, we 
extracted the drug prescriptions retrospectively for the 
period extending to January 1997, and ensured that all 
individuals had available data for at least 3  years before 
study inclusion.
Statistical analysis
The baseline demographics characteristics were com-
pared between groups. For categorical variables, Chi 
square test was used for analysis. For continuous vari-
ables, independent t test or Mann–Whitney U test were 
used. Odds radios (ORs) were used to compare the expo-
sure of OADs between cases and controls. For OAD 
users, cumulative dose was categorized into quintiles to 
explore the dose-response relationships. We conducted 
conditional logistic regression with adjustment for 
potential confounding factors, including prescriptions of 
alpha-blocker, ACE inhibitor or ARB, beta blocker, cal-
cium channel blocker, diuretics, antiplatelet agent, war-
farin, statin, steroid, antidepressants, NSAID, and insulin. 
Statistical significance was set at p < 0.05. For data link-
age, processing, and sampling, we used the Microsoft 
SQL Server 2012 (Microsoft Corp., Redmond, Washing-
ton, USA). All analyses were performed using STATA 
statistical software (version 13.0; StataCorp., College Sta-
tion, Texas, USA).
Results
We had identified 4468 cases of AA and 4468 controls 
with DM diagnosis between 2000 and 2013. The base-
line demographics were shown in Table 1. The mean age 
was 67.5  years and predominately male (66.5  %). While 
comparing other concomitantly prescribed medications, 
alpha-blockers, ACE inhibitors/ARBs, beta-blockers, cal-
cium channel blockers, diuretics, antiplatelets, warfarins, 
statins, and anti-depressants were more prevalent among 
cases than among controls.
Table  2 presents the crude and adjusted ORs for the 
development of AA in association with OAD use com-
pared with controls, after adjusting for all potential con-
founders in Table  1. Metformin use, sulfonylurea use, 
and TZD use were associated with lower risk of develop-
ing AA, adjusted OR 0.72 (95 % confidence interval [CI] 
0.64–0.80), 0.82 (95 % CI 0.74–0.92), and 0.82 (95 % CI 
0.69–0.98), respectively (Table  2). There was no asso-
ciation between developing of AA and alpha-glucosi-
dase inhibitors (adjusted OR 0.95; 95 % CI 0.81–1.11) or 
DPP-4 inhibitors (adjusted OR 0.85; 95 % CI 0.68–1.07).
We further examine the dosage effect. While strati-
fied by quantile according to the dose of OAD, the 
effect on AA was dose responsive for metformin (p for 
trend <0.001) and sulfonylurea (p for trend <0.001), but 
not for TZD (p for trend 0.431). The detailed results were 
shown in Table 3.
Discussion
In this retrospective, nested-case control study, we dem-
onstrated the associations of diverse classes of OADs in 
development of AA. After adjustment, occurrence of AA 
remains lower in those receiving metformin, sulfonylu-
rea, and TZD, but not DPP4 inhibitors and alpha-glucosi-
dase inhibitors. Dose-response relationships are seen in 
metformin and sulfonylurea treated groups.
Thompson et al. conducted a prospective observational 
study for drug effects on AA growth in 2010 [21]. Of the 
1296 patients followed for 3.4  years, exposure to hypo-
glycemic agents was associated with a slower AA growth 
rate (1.70 mm per year vs. 0.74 mm per year, estimated 
difference −0.95, 95  % CI −1.66 to −0.25). Since there 
were no differences between drug classes, he attributed 
the protective effect to DM, instead of OADs. An epide-
miologic study assessing risk factors for AA growth also 
revealed a 0.11  cm decrease in AA diameter per year 
among diabetic patients [22]. Others disclosed signifi-
cant lower incidence rate of AA and lower mortality in 
DM patients [23, 24]. However, the influence of OADs 
was not taken into consideration. In comparison, our 
study results show that patients receiving several classes 
of OADs, including metformin, sulfonylurea, and TZD 
have lower risks, but not in those treated with alpha-
glucosidase inhibitor or DPP-4 inhibitor. Besides, there 
is a dose-response relationships and metformin and sul-
fonylurea treated patients. The differences between drug 
classes and dose-response relationships provide new evi-
dence for the beneficial effects of OADs in AA.
Impacts of OADs on AA growth have been found in pre-
vious clinical and animal studies. Vasamsetti et  al. dem-
onstrated an attenuation of atheromatous plaque and AA 
formation in metformin treated ApoE(−/−) mice [11]. 
In the same experimental study, they found metformin 
induced AMPK activation. The subsequent inhibition of 
monocyte-to-macrophage differentiation and proinflam-
matory cytokine production may explain why metformin 
was able to protect the mice from aneurysm formation. 
More recently, Fujimura et  al. reported that metformin 
is associated with a below-median enlargement rate in 
abdominal AA patients in a population-based study [25]. 
They also demonstrated that metformin dramatically 
inhibited the formation and progression of aneurysm in an 
experimental model, which was shown by preservation of 
smooth muscle and reduction of aortic mural macrophage, 
CD8 T cell, and neovascularity [25]. Similar effect was seen 
in TZDs. Pirianov et al. demonstrated rosiglitazone treated 
ApoE(−/−) mice with lower incidence of development 
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and rupture of abdominal AA [26]. It was caused by inhib-
iting c-Jun N- terminal kinase phosphorylation and down-
regulating toll-like receptor four expression at the lesion 
site, leading to a decrease of CD4 antigen and reduction in 
proinflammatory chemokines production.
There was no direct clinical or experimental study 
discussing the possible mechanism of sulfonylurea’s 
protective effect to date. Based on our current under-
standing of pharmacologic effect of sulfonylurea, we 
suggest that the SUR2 receptor, mainly expressed in the 
smooth muscle cell wall might play a role. An indirect 
evidence to this assumption was seen in a family of Cantu 
syndrome reported by Hiraki et  al. [27]. They reported 
a family of Cantu syndrome, which is a genetic disorder 
Table 1 Characteristics of the cases and controls
a Urbanization levels in Taiwan are divided into four strata according to the Taiwan National Health Research Institute publications. Level 1 designates the most 
urbanized areas, and level 4 designates the least urbanized areas
b Charlson comorbidity index (CCI) score is used to determine overall systemic health. With each increased level of CCI score, there are stepwise increases in the 
cumulative mortality
c Adapted diabetes complications severity index is a 13-point scale from 7 complication categories: retinopathy, nephropathy, neuropathy, cerebrovascular, 
cardiovascular, peripheral vascular disease, and metabolic, ranging from each complication. Each complication produced a numeric score ranging from 0 to 2 (0 no 
abnormality, 1 some abnormality, 2 severe abnormality)
Cases Control p value
Patients (no.) 4468 4468
Age, mean (SD), years 67.5 (47.3) 67.5 (47.3) >0.99
Male sex 2969 (66.5) 2969 (66.5) >0.99
Monthly income
 Dependent 1614 (36.1) 1614 (36.1) >0.99
 0–19,100 NT dollars 1291 (28.9) 1291 (28.9)
 19,100–42,000 NT dollars 1454 (32.5) 1454 (32.5)
 > 42,000 NT dollars 109 (2.4) 109 (2.4)
Urbanizationa
 Level 1 1290 (28.9) 1290 (28.9) >0.99
 Level 2 3000 (67.1) 3000 (67.1)
 Level 3 158 (3.5) 158 (3.5)
 Level 4 20 (0.4) 20 (0.4)
Charlson comorbidity index scoreb (SD) 5.1 (2.6) 5.0 (2.5) 0.051
Adapted diabetes complications severity index scorec (SD) 2.7 (1.7) 2.6 (1.7) 0.057
Duration of diagnosis of diabetes mellitus, months (SD) 67.5 (47.3) 67.5 (47.3) >0.99
Other comorbidity
 Hypertension 4049 (90.6) 4049 (90.6) >0.99
 Myocardial infarction 463 (10.4) 463 (10.4) >0.99
 Cerebrovascular disease 2261 (50.6) 2261 (50.6) >0.99
 Chronic kidney disease 1529 (34.2) 1529 (34.2) >0.99
 Peripheral artery disease 395 (8.8) 395 (8.8) >0.99
Anti‑hypertensive drug use
 Alpha blocker 1619 (36.2) 1501 (33.6) 0.009
 ACE inhibitor or ARB 3538 (79.2) 3386 (75.8) <0.001
 Beta blocker 3571 (79.9) 3369 (75.4) <0.001
 Calcium channel blocker 3812 (85.3) 3596 (80.5) <0.001
 Diuretics 3345 (74.9) 3102 (69.4) <0.001
Antiplatelet agent 3751 (84.0) 3630 (81.2) 0.001
Warfarin 271 (6.1) 193 (4.3) <0.001
Statin 1976 (44.2) 1838 (41.1) 0.003
Antidepressants 1984 (44.4) 1826 (40.9) 0.001
Steroid 3870 (86.6) 3813 (85.3) 0.082
NSAID 4427 (99.1) 4426 (99.1) 0.912
Insulin 419 (9.4) 453 (10.1) 0.225
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characterized by ABCC9 mutation, affecting both SUR2A 
and SUR2B. One of the family members was presented 
with AA.
DPP-4 inhibitors treated individuals were not beneficial 
with regard to AA occurrence in our cohort. This is discrep-
ant to previous findings in animal studies. Bao et al. used 
alogliptin to treat their aneurysmal rats [13]. The alogliptin 
treated groups had a lower rate of aneurysm expansion, 
and fewer ROS, MMPs expression in aneurysm walls. Lu 
et al. also showed significantly fewer MMP-2 and MMP-9 
production, associated with lower incidence of ApoE(−/−) 
mice [14]. In addition, the beneficial effect of DPP-4 inhibi-
tors on major adverse cardiac events was shown in several 
studies [28, 29]. Since AA have been seen as a part of the 
spectrum of cardiovascular disease, we assumed DPP-4 
inhibitor might also possess protective effects on AA. 
There are three possible causes to explain the discrepancy. 
First, the duration of exposure to DPP-4 inhibitor may not 
be long enough. The first DPP-4 inhibitor was approved in 
Taiwan in 2009. Our case collection ended in 2013. Thus, 
the patients had only been taken DPP-4 inhibitor for less 
than 4 years. A longer follow up period is probably needed. 
Second, the case number may be too small. In patients 
enrolled in our study, only 163 individuals were prescribed 
with DPP-4 inhibitors in the aneurysm group, and 187 in 
the control group. The relatively small sample size is not 
enough to achieve an adequate power.
The strength of the current study is the inclusion of 
large cases representing the nationwide diabetes popu-
lations from 2000 to 2013, which thus minimized refer-
ral bias. Still, this study has several limitations. First, 
unmeasured confounding is the primary limitation 
inherent in the use of administrative data. Some lifestyle 
information and cardiovascular risk indicators such as 
smoking status, alcohol consumption, obesity, dietary 
habits, exercise condition and lipid profiles were not 
available through the administrative dataset. However, 
due to low incidence of AA, it is difficult to conduct a 
randomize control study with sufficient power. Second, 
information on indices of diabetes control, such as gly-
cosylated hemoglobin or fasting glucose level, was lack-
ing. Nevertheless, the observed associations between 
the risk of AA and different OADs with similar glucose 
lowering effects and indications were not all in the same 
direction. If the influence of OADs on aneurysm forma-
tion was mainly from the effect of the glucose-lowering, 
the tendency of ORs in different OADs should tend 
toward coherence. Furthermore, the duration and sever-
ity (evaluated by adapted diabetes complications severity 
index score) of type 2 DM were matched between study 
groups (shown in Table 1). Thus, it is less likely that this 
unmeasured confounder biased the results. Third, rel-
evant details regarding AA severity, such as AA diameter 
or annual rate of AA expansion, were not available in our 
administrative claims data set. AAs are often asympto-
matic in early stages, and they are imperceptible for gen-
eral population. For those, who may have small AA but 
without any symptom and without further diagnosis, 
would not have medical record in NHIRD. Hence, it may 
be underestimated the true prevalence and incidence of 
AA in Taiwan. Fourth, on account of the present retro-
spective and observational study design, we were unable 
to determine the direction of causality. Finally, compar-
ing with epidemiological studies in Western countries, 
our study showed a relatively low prevalence among Tai-
wanese population, which was consistent with previous 
studies from Asian countries (0.3–0.5 %) [30]. However, 
the prevalence and incident rate in Taiwan NHI database 
Table 2 Crude and adjusted rate ratios for the risk of aortic aneurysm with oral antidiabetic drugs
a Adjusted for using alpha blocker, ACE inhibitor or ARB, beta blocker, calcium channel blocker, diuretics, antiplatelet agent, warfarin, statin, steroid, antidepressants, 
NSAID, and insulin
b Use of one prescription at any time prior to the index date
No. (%) Odds ratio (95 % CI)
Cases (n = 4468) Control (n = 4468) Crude p value Adjusteda p value
No metformin useb 2882 2455 1 [Reference] 1 [Reference]
Metformin use 1586 2013 0.64 (0.58–0.70) <0.001 0.72 (0.64–0.80) <0.001
No DPP‑4 inhibitor useb 4305 4281 1 [Reference] 1 [Reference]
DPP‑4 use 163 187 0.85 (0.68–1.07) 0.168 1.07 (0.84–1.36) 0.582
No sulfonylurea useb 2779 2412 1 [Reference] 1 [Reference]
Sulfonylurea use 1689 2056 0.68 (0.62–0.75) <0.001 0.82 (0.74–0.92) 0.001
No alpha‑glucosidase inhibitors useb 4077 3999 1 [Reference] 1 [Reference]
Alpha‑glucosidase inhibitors use 391 469 0.81 (0.70–0.93) 0.004 0.95 (0.81–1.11) 0.507
No thiazolidinedione useb 4171 4065 1 [Reference] 1 [Reference]
Thiazolidinedione use 297 403 0.70 (0.59–0.82) <0.001 0.82 (0.69–0.98) 0.003
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were even lower than reported rates among other Asian 
countries [30]. The prevalence calculated from diagno-
sis-specific claim data might be lower than those epide-
miological data from the reports of screening programs. 
Therefore, the results from the present study are not nec-
essarily applicable on Caucasian populations given the 
lower prevalence of AA in Asian populations.
Conclusions
Oral antidiabetic agents, including metformin, sulfonylu-
rea, and TZD showed protective effects on abdominal AA 
development, but not DPP-4 inhibitors or alpha-glucosi-
dase inhibitor. The protective effects of OADs are further 
confirmed by the dose responsive relations in metformin 
and sulfonylurea groups. In the future, well-conducted 
Table 3 Crude and adjusted rate ratios for the risk of aortic aneurysm with oral antidiabetic drugs
a Adjusted for using alpha blocker, ACE inhibitor or ARB, beta blocker, calcium channel blocker, diuretics, antiplatelet agent, warfarin, statin, steroid, antidepressants, 
NSAID, and insulin
b Use of one prescription at any time prior to the index date
c Medians, interquartile range
Dosage No. (%) Odds ratio (95 % CI)
Cases (n = 4468) Control (n = 4468) Crude p value Adjusteda p value
No metformin useb 2882 2455 1 [Reference] 1 [Reference]
Metformin use (daysc) 1586 2013 0.64 (0.58–0.70) <0.001 0.72 (0.64–0.80) <0.001
 Quantile 1 (11, 6–17) 364 363 0.85 (0.73–0.99) 0.042 0.91 (0.78–1.08) 0.291
 Quantile 2 (56, 41–79) 326 400 0.66 (0.56–0.77) <0.001 0.71 (0.60–0.85) <0.001
 Quantile 3 (181, 139–233) 303 404 0.60 (0.51–0.70) <0.001 0.67 (0.56–0.81) <0.001
 Quantile 4 (459, 375–576) 316 404 0.60 (0.50–0.71) <0.001 0.70 (0.58–0.86) 0.001
 Quantile 5 (1127, 861–1666) 277 442 0.46 (0.38–0.55) <0.001 0.57 (0.45–0.72) <0.001
No DPP‑4 inhibitor useb 4305 4281 1 [Reference] 1 [Reference]
DPP‑4 use (daysc) 163 187 0.85 (0.68–1.07) 0.168 1.07 (0.84–1.36) 0.582
 Quantile 1 (25, 14–30) 45 28 1.58 (0.98–2.55) 0.062 1.99 (1.20–3.29) 0.007
 Quantile 2 (70, 56–84) 28 39 0.70 (0.43–1.15) 0.157 0.96 (0.57–1.62) 0.884
 Quantile 3 (140, 112–168) 31 40 0.74 (0.46–1.20) 0.224 1.00 (0.61–1.65) 0.992
 Quantile 4 (238, 210–273) 30 39 0.75 (0.46–1.22) 0.249 1.03 (0.62–1.72) 0.904
 Quantile 5 (509, 413–672) 29 41 0.70 (0.43–1.13) 0.143 1.01 (0.60–1.68) 0.978
No sulfonylurea useb 2779 2412 1 [Reference] 1 [Reference]
Sulfonylurea use (daysc) 1689 2056 0.68 (0.62–0.75) <0.001 0.82 (0.74–0.92) 0.001
 Quantile 1 (20, 9–37) 402 359 0.96 (0.83–1.12) 0.624 1.04 (0.88–1.23) 0.630
 Quantile 2 (120, 84–165) 336 401 0.70 (0.60–0.82) <0.001 0.81 (0.69–0.97) 0.018
 Quantile 3 (424, 313–544) 336 413 0.67 (0.57–0.79) <0.001 0.79 (0.66–0.95) 0.010
 Quantile 4 (1128, 881–1408) 312 437 0.55 (0.47–0.65) <0.001 0.71 (0.59–0.87) 0.001
 Quantile 5 (3164, 2329–4620) 303 446 0.51 (0.43–0.61) <0.001 0.74 (0.59–0.94) 0.014
No alpha‑glucosidase inhibitors useb 4077 3999 1 [Reference] 1 [Reference]
Alpha‑glucosidase inhibitors use (daysc) 391 469 0.81 (0.70–0.93) 0.004 0.95 (0.81–1.11) 0.507
 Quantile 1 (7, 5–10) 83 108 0.75 (0.56–1.00) 0.050 0.89 (0.66–1.21) 0.463
 Quantile 2 (28, 19–35) 79 77 0.99 (0.72–1.36) 0.948 1.14 (0.82–1.59) 0.448
 Quantile 3 (68, 56–85) 81 88 0.89 (0.66–1.22) 0.477 1.04 (0.76–1.44) 0.793
 Quantile 4 (164, 134–210) 79 93 0.83 (0.61–1.12) 0.212 1.03 (0.75–1.42) 0.861
 Quantile 5 (444, 344–630) 69 103 0.63 (0.45–0.87) 0.005 0.87 (0.61–1.23) 0.423
No thiazolidinedione useb 4171 4065 1 [Reference] 1 [Reference]
Thiazolidinedione use (daysc) 297 403 0.70 (0.59–0.82) <0.001 0.82 (0.69–0.98) 0.003
 Quantile 1 (19, 13–28) 71 69 0.97 (0.70–1.36) 0.873 1.12 (0.79–1.59) 0.518
 Quantile 2 (65, 56–84) 54 86 0.58 (0.41–0.83) 0.003 0.77 (0.53–1.12) 0.167
 Quantile 3 (206, 168–266) 54 87 0.59 (0.42–0.84) 0.003 0.77 (0.53–1.11) 0.164
 Quantile 4 (532, 413–630) 65 74 0.83 (0.59–1.16) 0.281 1.14 (0.79–1.63) 0.485
 Quantile 5 (1247, 977–1980) 53 87 0.57 (0.40–0.81) 0.002 0.80 (0.54–1.17) 0.241
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prospective studies are necessary to give stronger evi-
dence of the OADs protective effects on AA.
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